Eli Lilly & Co. sued Roche Holding AG (ROG)’s Genentech unit, asking a court to invalidate patents used to make treatments for cancer and autoimmune diseases and order that its Erbitux drug doesn’t infringe the patent.
Genentech deceived the U.S. Patent Office into issuing patents known as “Cabilly” after one of the inventors, Eli Lilly said in a complaint filed yesterday in federal court in San Francisco. Genentech claims that the process and certain starting materials used to produce Erbitux infringe parts of the patents, and is pursuing an “aggressive litigation policy to protect its products against competition,” according to the complaint.
Erbitux, made by Indianapolis-based Lilly’s ImClone unit, is approved in the U.S. to treat colon cancer and head and neck tumors.
“Lilly contends that it has no obligation to pay royalties on the sale of Erbitux” due to the “Cabilly patents being invalid and unenforceable, and, in any event, not infringed by Lilly,” Lilly said in the complaint.
A phone call to Genentech’s media office seeking comment about the lawsuit wasn’t immediately returned yesterday.
The case is Eli Lilly & Co. (LLY:US) v. Genentech Inc., 13-919, U.S. District Court, Northern District of California (San Francisco).
To contact the reporter on this story: Karen Gullo in San Francisco at firstname.lastname@example.org
To contact the editor responsible for this story: Michael Hytha at email@example.com